PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania into the TOBA II clinical on October 19, 2015. This trial is to assess the safety and efficacy of a vascular implant ...
Cilostazol exhibits its pharmacologic effects via antiplatelet, vasodilatory, and antithrombotic activities. Like pentoxifylline, cilostazol and several of its metabolites exhibit these antiplatelet ...
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease. We ...
Millions of Americans have peripheral artery disease, a disorder primarily caused by fatty deposits that can narrow arteries and block blood flow to the legs. Often, the first symptom they feel is leg ...
Exercise therapy -- preferably a supervised walking program -- should always be considered as part of the initial therapy for patients with intermittent claudication. [1] Regular walking can be ...
Drug-coated stents and balloons were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in two trials in peripheral artery disease (PAD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results